Alexion Pharmaceuticals
Headquartered in Cheshire, Connecticut (USA), Alexion is global biopharmaceutical company focused on the development and delivery of life-transforming therapies for patients with severe and life-threatening rare disorders.
Financial Data
-
31st Dec 19 Source: CRO
- €2.5 billion turnover
-
€1.5 billion
profit - 400 employees
-
31st Dec 18 Source: CRO
- €2.3 billion turnover
-
€1.3 billion
profit - 500 employees
- 5 more years available »
Ranking
By Turnover
(€2.5 billion)- 47th in Top Companies
- 10th in Health
- 6th in Pharma
By Employees
(400)- 429th in Top Companies
- 65th in Health
- 39th in Pharma
- 400
- €2.5 billion
Employees
- Shane Doyle Senior vice president
Latest News
- 5:15am Eir planning to sell almost half of Irish fibre network
- Oct 22 Methane leak near Cop26 venue underscores emissions challenge
- Oct 22 Goldman grants stock worth $30m in five years to chief David Solomon
- Oct 22 RDS hosts first large event since pandemic with return of Ideal Home Exhibition
- Oct 22 Ronan Group gets injunction preventing Digital Bridge selling Dublin stakes